Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Limited

Pharma Wisdom provides job updates in the pharmaceutical, life science, and healthcare industries, facilitating recruitment efforts.

Pharma Wisdom

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.

The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Rising Tide

Quadria Capital

Neuberger Berman

Critically ill patients on ventilators face a high risk of lower respiratory tract infections, such as ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). VAP is linked to increased morbidity and mortality in the ICU, emphasizing the need for prevention. 

This review examines the potential of pre-emptive aerosolized antibiotics (AA) in preventing ventilator-associated infections and whether aerosolized treatment for VAT can halt its progression to VAP. 

Read more: https://lnkd.in/dX6msByM 

#respiratoryinfections #ventilatorassociatedpneumonia #aerosolizedantibiotics #ventilatorassociatedtracheobronchitis #criticalcare #intensivecare

Concord Biotech stands united on World AIDS Day, spreading awareness and knowledge to foster a world free from HIV/AIDS. Together, let's strive for prevention, support, and a brighter, healthier future for all.

#WorldAIDSDAY2023
#WorldAIDSDay  #HIV #AIDS #HIVawareness #AIDSawareness

Tune in to today's episode of Good Health Conquest as we discuss the Role of the granzyme family in rheumatoid arthritis. Our spotlight turns to the granzyme family, specifically granzymes A, B, M, K, and the enigmatic granzyme H, shedding light on their potential role in rheumatoid arthritis pathogenesis.

Listen now: https://lnkd.in/d5UCpmhA
For more information, visit www.conquest.health

#RA #Rheumatoidarthritis #Granzyme #pathogenesis #podcast #Concordbiotech #GoodHealthConquest

On this Gurupurab, may the teachings of Guru Nanak Dev Ji inspire you to lead a life of compassion and righteousness. Happy Gurupurab!

#HappyGurupurab #Gurupurab #GuruNanakJayanti #HappyGuruNanakJayanti #ConcordBiotech

On today's episode of the Good Health Conquest, we discuss the Current Therapies in Kidney Transplant Rejection, specifically acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). Stay tuned as we navigate the evolving landscape of kidney transplantation, striving for improved long-term outcomes and a deeper understanding of rejection mechanisms.

Listen now: https://lnkd.in/dU-xVv2q Find us on all major listening platforms and apps. For more information, visit our website at www.conquest.health

#kidneytransplant #renaltransplant #treansplantrejection #rejection #posttransplant #kidneycomplications #Concordbiotech

While there are chances to enhance antibiotic prescribing throughout the care spectrum, the discharge phase from hospitalization is a notable contributor to antibiotic overuse. 

Thus, it becomes imperative to improve antibiotic prescribing by optimizing antibiotic selection, reassessing antibiotic treatment, and using the shortest effective duration of therapy post-discharge.  

#Antibioticresistance #AntimicrobialAwarenessWeek #AntimicrobialResistance #WorldAntimicrobialAwarenessWeek #WAAW #WAAW2023 #AMR

Metric
Company Name	Concord Biotech Limited	Pharma Wisdom
Symbol	CONCORDBIO
MSH ID	COM:CONCORDBIOTECH	IN:CO:PHARMAWISDOM
Market	STOCKS	PRIVATE
Sector	Healthcare	Commercial & Professional Services
Industry	Biotechnology	Healthcare
Country	IN	IN
Stage
Employee Count	1.38K
Website	concordbiotech.com	pharmawisdom.co.in
LinkedIn	concord-biotech-limited
Founders

Metric
Market Cap	2.09B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	120.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	72.15M
EBITDA	50.95M
Operating Income	44.62M
Net Income	36.38M
EPS	0.35
Diluted EPS	0.35
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.73
Operating Profit Margin	0.40
EBITDA Margin	0.42
Net Profit Margin	0.32
Return on Equity	0.23
Return on Assets	0.18
Return on Capital Employed	0.25

CONC

COM:CONCORDBIOTECH

Concord Biotech

Last Close

2,031.55

25/11 09:20

Market Cap

176.73B

Beta: -

Volume Today

7.43K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	51.37
P/B Ratio	11.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	26.17
EV Multiple	59.58

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	238.56
Operating Cycle	364.05
Cash Conversion Cycle	255.71
Asset Turnover	0.61

Metric
Operating Cash Flow	31.57M
Free Cash Flow	21.46M
Cash Flow to Debt	21.88
Operating Cash Flow/Sales	0.22
Free Cash Flow Yield	0.01

Metric
Cash & Equivalents	5.55M
Accounts Receivable	-9.29M
Inventory	24.55M
Goodwill
Debt to Capitalization	0.01
Debt to Assets
Current Ratio
Quick Ratio	4.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue